HALO vs. PCVX: Halozyme Therapeutics vs. Vaxcyte Stock Comparison

November 11, 2026

How do Halozyme Therapeutics (HALO) and Vaxcyte (PCVX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Halozyme Therapeutics (HALO) and Vaxcyte (PCVX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Halozyme Therapeutics (HALO) has more than two decades of public-market history since March 16, 2004, whereas Vaxcyte (PCVX) listed on June 12, 2020 and has a much shorter record to draw on.

Company profile comparison for Halozyme Therapeutics (HALO) and Vaxcyte (PCVX)
Profile Item	HALO	PCVX
Name	Halozyme Therapeutics Inc.	Vaxcyte Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Biotechnology
GICS Sub-Industry	Biotechnology	Biotechnology
Market Capitalization	11.81 billion USD	10.11 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	March 16, 2004	June 12, 2020
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

HALO

PCVX

GSPC

Halozyme Therapeutics (HALO) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Halozyme Therapeutics (HALO) and Vaxcyte (PCVX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Halozyme Therapeutics (HALO) and Vaxcyte (PCVX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Halozyme Therapeutics (HALO) and Vaxcyte (PCVX)
Metric	HALO	PCVX
Total Return (1Y)	50.94%	59.00%
Total Return (3Y, Annualized)	41.08%	11.29%
Total Return (5Y, Annualized)	21.68%	21.60%

Risk Profile

Drawdown History

HALO

PCVX

GSPC

Halozyme Therapeutics (HALO) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Halozyme Therapeutics (HALO) and Vaxcyte (PCVX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Halozyme Therapeutics (HALO) and Vaxcyte (PCVX)
Metric	HALO	PCVX
Volatility (1Y, Annualized)	41.19%	56.01%
Beta (5Y)	0.96	1.26
Max Drawdown (5Y)	-49.06%	-76.22%
Avg. Volume (3M)	2.29M	2.12M

Risk-Adjusted Performance

Risk-Return Positioning

HALO and PCVX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Halozyme Therapeutics (HALO) and Vaxcyte (PCVX)
Metric	HALO	PCVX
Sharpe Ratio (1Y)	1.13	0.98
Sortino Ratio (1Y)	1.78	1.76

Profitability

ROE (TTM)

Vaxcyte (PCVX) reports a negative ROE of -42.68%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Halozyme Therapeutics (HALO) reports 216.38%, ranking against industry peers normally.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

216.38%

HALO: 216.38%
Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
PCVX: -42.68%
Q1: -64.05%
Min: -167.77%

Halozyme Therapeutics (HALO) vs. Vaxcyte (PCVX): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Halozyme Therapeutics (HALO) at 26.93% converts revenue to bottom-line profit above its industry’s benchmark range, while Vaxcyte (PCVX) at 0.00% keeps roughly the typical share for its industry.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.93%

HALO: 26.93%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
PCVX: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Halozyme Therapeutics (HALO) vs. Vaxcyte (PCVX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Halozyme Therapeutics (HALO) at 59.84% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

59.84%

Max: 83.12%
HALO: 59.84%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 83.12%
Q3: 14.77%
PCVX: 0.00%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Halozyme Therapeutics (HALO) vs. Vaxcyte (PCVX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Halozyme Therapeutics (HALO) and Vaxcyte (PCVX)
Metric	HALO	PCVX
ROE (TTM)	216.38%	-42.68%
ROA (TTM)	22.42%	-24.98%
Net Margin (TTM)	26.93%	0.00%
Operating Margin (TTM)	59.84%	0.00%
Gross Margin (TTM)	77.74%	0.00%

Growth

Revenue Growth

Only one side can be read here: Halozyme Therapeutics (HALO) reports revenue growth of 37.55%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Halozyme Therapeutics (HALO) vs. Vaxcyte (PCVX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Halozyme Therapeutics (HALO) reports EPS growth of -25.36%, ranked against its industry; Vaxcyte (PCVX) has no EPS growth figure this period.

Halozyme Therapeutics (HALO) vs. Vaxcyte (PCVX): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Halozyme Therapeutics (HALO) and Vaxcyte (PCVX)
Metric	HALO	PCVX
Revenue Growth (YoY)	37.55%	--
Revenue Growth (3Y CAGR)	28.38%	--
EPS Growth (YoY)	-25.36%	--
EPS Growth (3Y CAGR)	21.14%	--

Financial Strength

Current Ratio (MRQ)

Both Halozyme Therapeutics (HALO) at 3.88 and Vaxcyte (PCVX) at 4.56 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.88

Max: 25.13
Q3: 12.13
Median: 5.52
HALO: 3.88
Q1: 2.47
Min: 0.10

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max: 25.13
Q3: 12.13
Median: 5.52
PCVX: 4.56
Q1: 2.47
Min: 0.10

Halozyme Therapeutics (HALO) vs. Vaxcyte (PCVX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Vaxcyte (PCVX) carries debt-to-equity ratio of 0.09 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
HALO: --

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max: 1.42
Q3: 0.65
Median: 0.15
PCVX: 0.09
Q1: 0.02
Min: 0.00

Halozyme Therapeutics (HALO) vs. Vaxcyte (PCVX): HALO does not report debt-to-equity ratio, so it has no value marker; PCVX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Halozyme Therapeutics (HALO) and Vaxcyte (PCVX)
Metric	HALO	PCVX
Current Ratio (MRQ)	3.88	4.56
Debt / Equity (MRQ)	--	0.09
Net Debt / EBITDA	1.90	--

Dividends

Dividend Yield (TTM)

Neither Halozyme Therapeutics (HALO) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

HALO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Halozyme Therapeutics (HALO) vs. Vaxcyte (PCVX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Halozyme Therapeutics (HALO) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

HALO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Halozyme Therapeutics (HALO) vs. Vaxcyte (PCVX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Halozyme Therapeutics (HALO) and Vaxcyte (PCVX)
Metric	HALO	PCVX
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Halozyme Therapeutics (HALO) trades at 25.91 times trailing earnings, ranked against its peers, while Vaxcyte (PCVX) has no P/E ratio this period.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.91

Max: 85.34
Q3: 43.46
Median: 26.69
HALO: 25.91
Q1: 13.30
Min: 0.07

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
PCVX: --

Halozyme Therapeutics (HALO) vs. Vaxcyte (PCVX): PCVX does not report P/E ratio, so it has no value marker; HALO is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

A sales-based read is only available for Halozyme Therapeutics (HALO), whose P/S ratio of 6.55 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.55

Max: 58.18
Q3: 25.77
Median: 7.30
HALO: 6.55
Q1: 3.01
Min: 0.01

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01
PCVX: --

Halozyme Therapeutics (HALO) vs. Vaxcyte (PCVX): PCVX does not report P/S ratio, so it has no value marker; HALO is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Vaxcyte (PCVX) reports 3.83, ranking against industry peers normally.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-213.67

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59
HALO: -213.67

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max: 13.53
Q3: 6.54
PCVX: 3.83
Median: 3.25
Q1: 1.69
Min: -5.59

Halozyme Therapeutics (HALO) vs. Vaxcyte (PCVX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Halozyme Therapeutics (HALO) and Vaxcyte (PCVX)
Metric	HALO	PCVX
P/E Ratio (TTM)	25.91	--
P/S Ratio (TTM)	6.55	--
P/B Ratio (MRQ)	-213.67	3.83
Free Cash Flow Yield (TTM)	3.48%	-5.24%